Sonoma Pharmaceuticals (SNOA) Total Non-Current Liabilities (2011 - 2025)

Sonoma Pharmaceuticals' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $4.7 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities rose 25.62% year-over-year to $4.7 million; the TTM figure through Dec 2025 stood at $4.7 million (up 25.62% YoY), while the FY2025 annual figure was $4.1 million, up 6.34% from the prior year.
• Total Non-Current Liabilities was $4.7 million for Q4 2025 at Sonoma Pharmaceuticals, roughly flat from $4.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $6.3 million in Q1 2022 to a low of $3.3 million in Q4 2023.
• Historically, Total Non-Current Liabilities has averaged $4.5 million across 5 years, with a median of $4.3 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities plunged 36.31% in 2023, then soared 38.62% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $4.4 million in 2021, then declined by 3.5% to $4.3 million in 2022, then retreated by 21.93% to $3.3 million in 2023, then increased by 12.8% to $3.8 million in 2024, then climbed by 25.62% to $4.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $4.7 million (Q4 2025), $4.7 million (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.